BioChem Pharma's first-half results:
This article was originally published in Clinica
Executive Summary
BioChem Pharma, the Canadian target of much takeover speculation in recent weeks, has reported sales of Can$93.8 million ($69 million) in the first half, up from Can$39.5 million last year, supported by its acquisition in 1994 of Serono Diagnostics. BioChem's net loss fell to Can$3.3 million compared with Can$4.6 million. BioChem has denied rumours of a takeover approach from UK-based Glaxo Wellcome (see Clinica No 668, p 17).